AAAMS

FEBRUARY 22, 2023

Office politics are reduced as complex hierarchies are no longer present. You’ll Enter a Hot Market The global market for medical aesthetics is booming. Driven by pandemic-related trends that have normalized virtual work environments, market analysts are documenting record-breaking demand for aesthetic procedures.

Work-Life Balance 52

Work-Life Balance Training Office Marketing 52

The Dermatology Digest

APRIL 1, 2024

“We are excited to announce the addition of this collaboration for povorcitinib, expanding our relationship with CMS in the Dermatology space beyond ruxolitinib cream, to include two products with the potential to help patients with limited treatment options,” says Hervé Hoppenot, Chief Executive Officer, Incyte, in a news release.

Portfolios 36

Portfolios Injections Innovations Sales 36

The Dermatology Digest

DECEMBER 21, 2023

and Europe will complement the recent launch of Nuceiva, our flagship neurotoxin, which has been met with very strong interest and growing demand from customers,” says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release. “We “The addition of the Estyme facial fillers in the U.K. to now include the U.K.

Marketing 36

Marketing Sales Branding Portfolios 36

The Dermatology Digest

DECEMBER 21, 2023

and Europe will complement the recent launch of Nuceiva, our flagship neurotoxin, which has been met with very strong interest and growing demand from customers,” says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release. “We “The addition of the Estyme facial fillers in the U.K. to now include the U.K.

Marketing 36

Marketing Sales Branding Portfolios 36

The Dermatology Digest

OCTOBER 1, 2024

“We are encouraged by the outcome from the recent FDA meeting and the opportunity to advance our development of prabotulinumtoxinA utilizing the 351(k) biosimilar regulatory pathway,” says Marc Forth, AEON’s President and Chief Executive Officer, in a news release. “We

Hydration 36

Hydration Portfolios Office Surgery 36

Aesthetics Advisor

SEPTEMBER 15, 2023

It’s pure commonsense ,” Nathan Jones, chief executive officer of Xlear said in a statement. Moreover, Glenmark Pharmaceuticals received manufacturing and marketing approval for the Nitric Oxide Nasal Spray (NONS) as part of an accelerated approval process. Iota-carrageenan is a sugar that comes from algae. the South-African or B.1.351,

Hospital 69

Hospital Clinic Marketing Medical 69

The Dermatology Digest

NOVEMBER 4, 2024

“The MDR CE Mark certification for Estyme , is a critical milestone in our strategic path to expand our product portfolio and reflects our commitment to delivering high-quality gels that adhere to the most rigorous regulatory standards,” says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release.

Injections 68

Injections Medical Portfolios Branding 68

The Dermatology Digest

FEBRUARY 13, 2025

This milestone represents an exciting new chapter in our long-term strategy to expand our portfolio and transition from a single-product company to a multi-product innovator, strengthening our leadership in performance beauty, says David Moatazedi, President and Chief Executive Officer of Evolus, in a news release. market in Q2 2025.

Injections 73

Injections Portfolios Innovations Safety 73

The Dermatology Digest

MARCH 27, 2025

We are thrilled to announce this agreement with Kaken, a dermatology leader with significant reach and expertise in the Japanese market, says Martin Babler, President and Chief Executive Officer of Alumis, in a news release. Learn more about ESK-001 in psoriasis With Dr.Andrew Blauvelt here.

Pharmaceutical 36

Pharmaceutical Portfolios Clinic Safety 36